Announcement no. 8/2016


Interim Financial Report, 9M 2015/16 - See enclosed pdf.

 

Highlights

 

·       Organic revenue growth was 7%. Revenue in DKK was up by 6% to DKK 10,942m.

·       Organic growth rates by business area: Ostomy Care 9%, Continence Care 5%, Urology Care 8% and Wound & Skin Care 7%.

·       Gross profit was up by 6% to DKK 7,471m, equal to a gross margin of 68% (9M 2014/15: 68%). At constant exchange rates, the gross margin was 69%, against 68% in 9M 2014/15.

·       EBIT was up by 8% to DKK 3,562m, with the EBIT margin at 33%, compared with 32% in the same period of last year. At constant exchange rates, the EBIT margin was also 33%, against 32% in 9M 2014/15.

·       The net profit for the reporting period was up by 17% to DKK 2,719m, while diluted earnings per share were also up by 17% to DKK 12.78.

·       The free cash flow amounted to DKK 1,643m, DKK 307m (16%) less than in the same period of last year.

·       ROIC after tax before special items was 46%, which was in line with the same period of last year.

 

Financial guidance for 2015/16

 

·       We continue to expect organic revenue growth of 7–8% at constant exchange rates and now of about 6% in DKK from previously 6-7%.

·       We continue to expect the EBIT margin to be 33–34% at constant exchange rates and to be about 33% in DKK.

·       Capital expenditure is still expected to be DKK 600–700m.

·       The effective tax rate is still expected to be about 23%.


Attachments

9M_201516 Earnings release.pdf